SI2813491T1 - Derivati cikloalkana - Google Patents

Derivati cikloalkana

Info

Publication number
SI2813491T1
SI2813491T1 SI201330423A SI201330423A SI2813491T1 SI 2813491 T1 SI2813491 T1 SI 2813491T1 SI 201330423 A SI201330423 A SI 201330423A SI 201330423 A SI201330423 A SI 201330423A SI 2813491 T1 SI2813491 T1 SI 2813491T1
Authority
SI
Slovenia
Prior art keywords
cycloalkane derivative
cycloalkane
derivative
Prior art date
Application number
SI201330423A
Other languages
English (en)
Slovenian (sl)
Inventor
Tsuyoshi Shinozuka
Hiroyuki Kobayashi
Sayaka Suzuki
Kyosuke Tanaka
Hiroko Kimoto
Yuki Domon
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Publication of SI2813491T1 publication Critical patent/SI2813491T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201330423A 2012-02-09 2013-02-08 Derivati cikloalkana SI2813491T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012025754 2012-02-09
JP2012259122 2012-11-27
EP13746373.3A EP2813491B1 (en) 2012-02-09 2013-02-08 Cycloalkane derivative
PCT/JP2013/052985 WO2013118854A1 (ja) 2012-02-09 2013-02-08 シクロアルカン誘導体

Publications (1)

Publication Number Publication Date
SI2813491T1 true SI2813491T1 (sl) 2017-02-28

Family

ID=48947609

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330423A SI2813491T1 (sl) 2012-02-09 2013-02-08 Derivati cikloalkana

Country Status (30)

Country Link
US (3) US8889741B2 (Direct)
EP (2) EP3144300B1 (Direct)
JP (2) JP5997710B2 (Direct)
KR (1) KR20140127238A (Direct)
CN (1) CN104185629B (Direct)
AU (1) AU2013218592B2 (Direct)
BR (1) BR112014019478A2 (Direct)
CA (1) CA2864222C (Direct)
CO (1) CO7151511A2 (Direct)
CY (1) CY1118572T1 (Direct)
DK (1) DK2813491T3 (Direct)
ES (2) ES2613078T3 (Direct)
HR (1) HRP20161713T1 (Direct)
HU (2) HUE037048T2 (Direct)
IL (1) IL234014A (Direct)
IN (1) IN2014MN01577A (Direct)
LT (1) LT2813491T (Direct)
MX (1) MX349354B (Direct)
NZ (1) NZ628096A (Direct)
PH (2) PH12014501804A1 (Direct)
PL (1) PL2813491T3 (Direct)
PT (1) PT2813491T (Direct)
RS (1) RS55671B1 (Direct)
RU (1) RU2635354C2 (Direct)
SG (1) SG11201404707VA (Direct)
SI (1) SI2813491T1 (Direct)
SM (2) SMT201700053T1 (Direct)
TW (1) TWI612042B (Direct)
WO (1) WO2013118854A1 (Direct)
ZA (1) ZA201405801B (Direct)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
PE20150400A1 (es) 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
MX2015011436A (es) 2013-03-14 2016-06-06 Genentech Inc Triazolopiridinas sustituidas y metodos para usarlas.
BR112015022385A2 (pt) * 2013-03-14 2017-07-18 Daiichi Sankyo Co Ltd droga para uma doença respiratória
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10179767B2 (en) 2015-05-22 2019-01-15 Genentech, Inc. Substituted benzamides and methods of use thereof
MA42683A (fr) 2015-08-27 2018-07-04 Genentech Inc Composés thérapeutiques et leurs méthodes utilisation
SG10202007787RA (en) 2015-09-28 2020-09-29 Genentech Inc Therapeutic compounds and methods of use thereof
KR20180080187A (ko) * 2015-11-06 2018-07-11 다이이찌 산쿄 가부시키가이샤 디메톡시벤질기의 탈리 방법
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック, インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3458449B1 (en) * 2016-05-20 2025-03-05 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR20190078587A (ko) * 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
KR102561076B1 (ko) * 2016-10-27 2023-07-28 브리스톨-마이어스 스큅 컴퍼니 아실 술폰아미드 NaV1.7 억제제
AU2017371674B2 (en) * 2016-12-09 2021-07-22 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
KR102796209B1 (ko) 2017-09-20 2025-04-16 에이비엠 쎄라퓨틱스 코포레이션 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
US11028075B2 (en) 2018-02-26 2021-06-08 Genentech, Inc. Therapeutic compounds and methods of use thereof
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
UA127024C2 (uk) 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
BR112021000209A2 (pt) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Compostos de sulfonamida substituída por heteroarila e seu uso como agentes terapêuticos
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
MX2021007425A (es) 2018-12-26 2021-08-05 Raqualia Pharma Inc Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
US20240241265A1 (en) * 2023-01-18 2024-07-18 Qualcomm Incorporated Virtual positioning signal measurements

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222048B1 (en) 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
MX2007014486A (es) * 2005-05-16 2008-02-12 Vertex Pharma Derivados biciclicos como moduladores de canales ionicos.
WO2009012242A2 (en) 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
WO2010035166A1 (en) 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
MY157017A (en) * 2009-01-12 2016-04-15 Pfizer Ltd Sulfonamide derivatives
CA2804593C (en) * 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
US9145407B2 (en) * 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドPfizer Limited 化合物
KR20140091022A (ko) * 2011-10-31 2014-07-18 제논 파마슈티칼스 인크. 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도
US8889741B2 (en) * 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives

Also Published As

Publication number Publication date
ZA201405801B (en) 2015-12-23
LT2813491T (lt) 2017-02-10
CN104185629B (zh) 2017-10-13
PT2813491T (pt) 2017-02-10
SMT201700053B (it) 2017-03-08
HRP20161713T1 (hr) 2017-02-10
JP6154052B2 (ja) 2017-06-28
HK1203503A1 (en) 2015-10-30
US20140045862A1 (en) 2014-02-13
JP5997710B2 (ja) 2016-09-28
CO7151511A2 (es) 2014-12-29
HUE031450T2 (en) 2017-07-28
IL234014A0 (en) 2014-09-30
RU2014136463A (ru) 2016-03-27
ES2613078T3 (es) 2017-05-22
EP2813491A1 (en) 2014-12-17
BR112014019478A2 (pt) 2019-05-28
CA2864222C (en) 2016-10-25
IL234014A (en) 2017-09-28
CY1118572T1 (el) 2017-07-12
MX349354B (es) 2017-07-24
IN2014MN01577A (Direct) 2015-05-08
TWI612042B (zh) 2018-01-21
SMT201700053T1 (it) 2017-03-08
AU2013218592B2 (en) 2016-12-22
AU2013218592A1 (en) 2014-09-18
US20170001984A1 (en) 2017-01-05
PH12014501804B1 (en) 2014-11-17
RU2635354C2 (ru) 2017-11-13
US9493448B2 (en) 2016-11-15
RS55671B1 (sr) 2017-06-30
NZ628096A (en) 2016-06-24
JPWO2013118854A1 (ja) 2015-05-11
EP3144300A1 (en) 2017-03-22
US8889741B2 (en) 2014-11-18
PL2813491T3 (pl) 2017-08-31
TW201339152A (zh) 2013-10-01
PH12014501804A1 (en) 2014-11-17
WO2013118854A1 (ja) 2013-08-15
DK2813491T3 (en) 2017-02-13
PH12015502675A1 (en) 2017-04-24
EP3144300B1 (en) 2017-12-20
EP2813491A4 (en) 2015-08-12
JP2017008093A (ja) 2017-01-12
EP2813491B1 (en) 2016-11-02
CA2864222A1 (en) 2013-08-15
HUE037048T2 (hu) 2018-08-28
US9845313B2 (en) 2017-12-19
MX2014009637A (es) 2015-06-23
CN104185629A (zh) 2014-12-03
SG11201404707VA (en) 2014-10-30
ES2659434T3 (es) 2018-03-15
KR20140127238A (ko) 2014-11-03
US20150018551A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
ZA201405801B (en) Cycloalkane derivative
ZA201407694B (en) Substituted pyrrolidine-2-carboxamides
DK3327112T3 (en) Agse-deficient stamme
IL238221A0 (en) self-injector
SG11201404344XA (en) Substituted pyrrolidine-2-carboxamides
GB201220843D0 (en) Compound
EP2874517A4 (en) SEAT LIFTING ARRANGEMENT
SG11201406871UA (en) Benzamide derivative
IL236295A (en) The history of indanesulfamide
EP2905847A4 (en) TOGETHER
EP2934541A4 (en) NORIBOGAINE SUBSTITUTE
EP2920142A4 (en) MÉTHANOFULLERRÈNES
ZA201405108B (en) Substituted phenylazole derivative
PT2873660T (pt) Derivado de indolecarboxamida
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
GB201216448D0 (en) Compound
GB201211594D0 (en) Language
GB201219170D0 (en) Pull
GB201220595D0 (en) Keysafe application
GB201222353D0 (en) Auto-injector
GB201213503D0 (en) Auto-injector
GB201213502D0 (en) Auto-injector
GB201213500D0 (en) Auto-injector
GB201213498D0 (en) Auto-injector